Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Small Hydrophobic (SH) protein of Respiratory Syncytial Virus (RSV) subgroup A is a 64-65 amino acid type II transmembrane protein that functions as a viroporin, forming pentameric ion channels in host cell membranes (Gan et al., 2012, Protein & Cell). While the SH protein is not essential for viral replication in vitro, it plays a critical role in vivo by modulating host immune responses, such as inhibiting Tumor Necrosis Factor-alpha (TNF-alpha) signaling to prevent early apoptosis of infected cells (Fuentes et al., 2007, Journal of Virology). The extracellular C-terminal domain, known as SHe, consists of approximately 23 amino acids and is highly conserved within RSV subgroup A (Schepens et al., 2014, Nature Communications). SHe has become a significant therapeutic target because it is expressed on the surface of infected cells but is relatively shielded from the immune system during natural infection. Experimental vaccines targeting SHe do not induce neutralizing antibodies but instead trigger antibody-dependent cellular cytotoxicity (ADCC), leading to the clearance of infected cells and reduced viral load (Schepens et al., 2011, EMBO Molecular Medicine). This target is particularly relevant for developing broad-spectrum RSV prophylaxis to prevent severe lower respiratory tract infections like bronchiolitis and pneumonia.
Induction of antibody-dependent cellular cytotoxicity (ADCC) against RSV-infected cells and potential inhibition of viroporin-mediated ion channel function (Schepens et al., 2011, EMBO Molecular Medicine).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small hydrophobic protein ectodomain of Respiratory Syncytial Virus subgroup A (SHe).